|
⚲
|
| Keyboard |
| Patient Square Capital LP
✚
|
|
|---|---|
| CRD # | 312203 |
| SEC # | 801-120508 |
| CIK # | 0001819257, 0001827614 |
| AUM | 17.51 B (2026-05-26) |
| Employees | 97 (52% Investors, 3% Brokers) |
| Phone | 650-677-8100 |
| Address | 2884 Sand Hill Road Menlo Park, CA 94025 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Roivant Sciences Ltd | 226.2 | ||
| Argenx SE | 26.8 | ||
| Insmed Inc | 25.8 | ||
| BeiGene Ltd | 23.9 | ||
| UNUM Therapeutics Inc | 22.9 | ||
| Mirum Pharmaceuticals Inc | 21.2 | ||
| Belite Bio Inc | 18.6 | ||
| Legend Biotech Corp | 17.9 | ||
| Nektar Therapeutics | 15.1 | ||
| DBV Technologies Sa | 14.5 | ||
| View All | |||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | 27 Patient Square Paradigm Coinvest LP | [2026-03-31] | 500.0 M | |
| Filed 2025-02-28 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | 28 Patient Square Premium Coinvest LP | [2026-03-31] | 50.0 M | |
| Filed 2025-11-14 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | 29 Blackwell Capital Partners II LP | [2026-03-31] | 1,517.6 M | |
| Filed 2025-08-13 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | 30 Redwood Capital Discretionary Partners LP | [2026-03-31] | 13.8 M | |
| Filed 2025-08-13 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | 20 Patient Square Equity Executives II LP | 2025-03-26 | ||
| PE | 21 Patient Square Equity Executives QP II LP | [2025-03-26] | ||
| Filed 2026-03-30 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | 22 Patient Square Equity Partners II LP | [2025-03-26] | 3,111.0 M | 1,510.7 M |
| Filed 2025-08-29 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | 23 Patient Square Equity Partners II-A LP | [2025-03-26] | 3,111.0 M | 1,510.7 M |
| Filed 2025-08-29 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | 24 Patient Square Equity Partners II-B LP | 2025-03-26 | 297.6 M | |
| PE | 25 Patient Square Equity Co-Invest II LP | [2025-03-26] | 61.2 M | 61.2 M |
| Filed 2025-11-18 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 30 | 17.5 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 30 | 17.5 |
| By Discretionary | ||
| Discretionary | 30 | 17.5 |
| Non-Discretionary | 0 | 0.0 |
| Total | 30 | 17.5 |
| By Non-United States Persons | ||
| Non-United States Persons | 6.9 | |
| United States Persons | 10.7 | |
| Total | 30 | 17.5 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| James Momtazee | Executive Officer | 44 | 3 | |
| Adam Fliss | Executive Officer | 35 | 2 | |
| Maria Walker | Executive Officer | 24 | 2 | |
| Carolyn Drayer-Greenwalt | Executive Officer | 4 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001819257] | |
| 3 | [0001827614] | |
| 4 | [0001827614] | |
| SC 13G | [0001827614] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Patient Square Capital LLC | Montes Archimedes Acquisition Corp | [2021-02-11] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Private Equity |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Montes Archimedes Acquisition Corp | |
| Patient Square Capital LLC |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Montes Archimedes Acquisition Corp MAAC
Class B common stock · derivative
|
2021-09-30 | Grant | 10,167,956 | ||
|
Montes Archimedes Acquisition Corp MAAC
Class B common stock · derivative
|
2020-11-20 | Other | 1,232,044 |
| Comparable Firms | State | AUM |
|---|---|---|
|
American Securities LLC
✚
|
NY | 18.91 B |
|
Monroe Capital Management Advisors LLC
✚
|
IL | 18.56 B |
|
1823 Partners US LLC
✚
|
FL | 18.53 B |
|
Arctos Partners LP
✚
|
TX | 18.22 B |
|
RCP Advisors 2 LLC
✚
|
TX | 18.21 B |
|
Arlington Management Employees LLC
✚
|
MD | 18.19 B |
|
Atlas FRM LLC
✚
|
CT | 18.12 B |
|
Invesco Loan Manager LLC
✚
|
NY | 17.69 B |
|
Searchlight Capital Partners LP
✚
|
NY | 17.51 B |
|
Niobrara Capital Partners LP
✚
|
NY | 17.07 B |